Factors for the Growth of Pharmaceutical Expenditures Reimbursed by Public Funds: Methods and Models for Reducing Them
DOI:
https://doi.org/10.37075/RP.2008.2.08Abstract
This paper discuses some of the economic factors for the growth of pharmaceutical expenditures in the end of the last and the beginning of the 21 century. It gives special attention to inequality of income allocation as a factor for implementing comprehensive health insurance coverage. It is demonstrated that this process lead to increasing of the rate of moral hazard of costumers and thus to the growth of pharmaceutical expenditures. The market failures typical for pharmaceutical market have been analyzed as additional causes for government influence. Methods and models for restricting the pharmaceutical expenditures in public sector, available in developed countries, are discussed. The measures influencing supply, demand and pure market tools are subject of special attention. As sources are used Bulgarian and International literature, periodicals, monographic issues, scientific researches and Internet stores.References
Kotler, Philip (2002). Marketing Management: Structure of Market Offering Management. Sofia: Klasika i Stil. ISBN: 954-9964-19-1
Maria Madzharova (2007). Influence of the Reference Price System on the Pharmaceutical Market. Economic Alternatives.
Order on the criteria, conditions, and rules for including medicinal products in the positive drug list in the Republic of Bulgaria. URL: https://www.nhif.bg/upload/1610/naredba_lek_poz_spis.doc (accessed 2009-05-15)
Order on the Conditions and Procedure for Concluding Agreements for Medicinal Products, Medical Devices, and Specialized Dietary Foods for Medical Purposes, the Value of Which is Fully or Partially Reimbursed by H3OK, State Gazette no. 61 from 2005.
Stiglitz, Joseph E. (1997). Economics of the Public Sector. Sofia: University Publishing House "Stopanstvo". ISBN: 954-494-212-2
Corinne B. & Kanavos P. (2001). France Pharmaceutical Pricing and Reimbursement. London School of Economics. URL: https://plg-group.com/wp-content/uploads/2014/03/France-Pharmaceutical-Pricing-and-Reimbursement-Corinne-Bl.pdf (accessed 2009-01-15)
Danzon, P. (2001). Reference Pricing: Theory and Evidence. Frontiers in Health Policy Research, Volume 7, pp. 1-54.
Traycho Stefanov Spasov (2004). Microeconomics. Sofia: University Publishing House "Stopanstvo". ISBN: 954-494-509-1
Danzon, P. (1999). The Pharmaceutical Industry. The Wharton School, University of Pennsylvania.
Danzon, Patricia M. (1997). Price Discrimination for Pharmaceuticals: Welfare Effects in the US and EU. International Journal of the Economics of Business, 4(3), 301-322. DOI: https://doi.org/10.1080/758523212
Danzon, P. & Kim, J. (2002). The Life Cycle of Pharmaceuticals: A Cross-National Perspective. Monograph. URL: https://ideas.repec.org//p/ohe/monogr/000480.html (accessed 2009-01-15)
Danzon, P. & Pauly, M. (2000). Health Insurance and the Growth in Pharmaceutical Expenditures. The Journal of Law and Economics, 45(S2), 587-613. DOI: https://doi.org/10.1086/368005
Dormont, Brigitte, Martins, Joaquim Oliveira, Pelgrin, Florian, & Suhrcke, Marc (2007). Health expenditures, longevity and growth. SSRN Electronic Journal. DOI: https://doi.org/10.2139/ssrn.1130315
Kanavos, P. (2003). Pharmaceutical regulation in Europe. London School of Economics and Political Science Research Online (London School of Economics and Political Science).
Nalebuff, Barry J. & Stiglitz, Joseph E. (1983). Information, competition and markets. The American economic review, 73(2), 278-283. DOI: https://doi.org/10.7916/d83b6946
Scott Morton, F. (2004). The Problems of Price controls. Health and Medicine Journal. DOI: https://doi.org/10.2139/ssrn.267243
Chalcraft, Anthony (2003). The Encyclopedia of Population. Reference Reviews, 18(3), 21-22. DOI: https://doi.org/10.1108/09504120410528054
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Veselin Tsvetkov (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright to their works.
All publications are distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) license.
